Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of 1-Naphthol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 2/20 | 0.48 |
| ▸ | ESR2 known ✓ | Q92731 | 2/20 | 0.48 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.47 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.47 |
| ▸ | PIK3CA known ✓ | P42336 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.94 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.61 |
| ▸ | IDO1 | P14902 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 2/20 | 0.52 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | SNCA | P37840 | 1/20 | 0.52 |
| ▸ | NQO2 | P16083 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1-Naphthol SCHEMBL30657150 | 1.00 | CYP1A2 (0.94) | CYP1A2PTPN22IDO1HSD17B10TDP1 | |
| 1-Naphthol SCHEMBL27269259 | 0.97 | CYP1A2 (0.90) | CYP1A2PTPN22IDO1HSD17B10TDP1 | |
| 1-Naphthol SCHEMBL6896129 | 0.97 | CYP1A2 (0.90) | CYP1A2PTPN22IDO1HSD17B10TDP1 | |
| 1-Naphthol SCHEMBL10486461 | 0.97 | CYP1A2 (1.00) | CYP1A2PTPN22IDO1HSD17B10TDP1 | |
| 1-Naphthol SCHEMBL3416 | 0.97 | CYP1A2 (1.00) | CYP1A2PTPN22IDO1HSD17B10TDP1 | |
| 1-Naphthol SCHEMBL273260 | 0.97 | CYP1A2 (1.00) | CYP1A2PTPN22IDO1HSD17B10TDP1 | |
| 1-Naphthol SCHEMBL29767730 | 0.97 | CYP1A2 (1.00) | CYP1A2PTPN22IDO1HSD17B10TDP1 | |
| 1-Naphthol SCHEMBL8904232 | 0.94 | CYP1A2 (0.94) | CYP1A2PTPN22IDO1HSD17B10TDP1 | |
| 1-Naphthol SCHEMBL3924043 | 0.94 | CYP1A2 (0.94) | CYP1A2PTPN22IDO1HSD17B10TDP1 | |
| 1-Naphthol SCHEMBL21490911 | 0.94 | CYP1A2 (0.94) | CYP1A2PTPN22IDO1HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114235990-A | Tuberculosis serum marker screening method and application | 宁夏医科大学 | 2022-03-25 | — | — | CN | claimed |
| CN-112209838-A | Preparation method of butenaphthol hydrochloride | 鲁南制药集团股份有限公司 | 2021-01-12 | — | — | CN | claimed |
| CN-118045162-A | Application of decorin combined with NK cells in treatment of solid tumors | 北京景达生物科技有限公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-114269756-B | 4-Oxo-3, 4-dihydropyrido [3,4-D ] pyrimidine compounds that inhibit EIF4E | 效应疗法股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117357503-B | Use of p-hydroxyphenylacetamide in the treatment of psychotic disorders | 中国人民解放军军事科学院军事医学研究院 | 2024-03-08 | — | — | CN | disclosed |
| CN-117545748-A | Benzimidazolyl GLP-1GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods of use thereof | 卡莫特医疗有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-117357503-A | Use of p-hydroxyphenylacetamide in the treatment of psychotic disorders | 中国人民解放军军事科学院军事医学研究院 | 2024-01-09 | — | — | CN | disclosed |
| CN-117043154-A | GPCR receptor agonists, pharmaceutical compositions comprising same, and methods of use thereof | 卡莫特医疗有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-114235990-A | Tuberculosis serum marker screening method and application | 宁夏医科大学 | 2022-03-25 | — | — | CN | disclosed |
| CN-111183134-A | Heterocyclic compound and organic light-emitting device comprising the same | LT素材株式会社 | 2020-05-19 | — | — | CN | disclosed |
| US-8704348-B2 | Polyol photosensitizers, carrier gas UV laser ablation sensitizers, and other additives and methods for making and using same | NDSU RESEARCH FOUNDATION (US) | 2014-04-22 | — | — | US | disclosed |
| US-8114567-B2 | Polyol photosensitizers, carrier gas UV laser ablation sensitizers, and other additives and methods for making and using same | NDSU RESEARCH FOUNDATION (US) | 2012-02-14 | — | — | US | disclosed |
| US-20090184417-A1 | POLYOL PHOTOSENSITIZERS, CARRIER GAS UV LASER ABLATION SENSITIZERS, AND OTHER ADDITIVES AND METHODS FOR MAKING AND USING SAME | NDSU RESEARCH FOUNDATION | 2009-07-23 | — | — | US | disclosed |
| WO-2007124073-A2 | POLYOL PHOTOSENSITIZERS, CARRIER GAS UV LASER ABLATION SENSITIZERS, AND OTHER ADDITIVES AND METHODS FOR MAKING AND USING SAME | NDSU RESEARCH FOUNDATION (US) | 2007-11-01 | — | — | WO | disclosed |
| CN-1747944-A | Blue light-emitting compound, method for producing same, and light-emitting element using same | HIROSE ENGINEERING CO LTD (JP) | 2006-03-15 | — | — | CN | disclosed |
| WO-2000056691-A1 | SYNTHESIS OF VAPOL LIGANDS | ARCH DEVELOPMENT CORPORATION (US) | 2000-09-28 | — | — | WO | disclosed |
| EP-0476016-A1 | THERAPEUTICALLY USEFUL 2-AMINOTETRALIN DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 1992-03-25 | — | — | EP | disclosed |
| WO-1990015047-A1 | THERAPEUTICALLY USEFUL 2-AMINOTETRALIN DERIVATIVES | THE UPJOHN COMPANY (US) | 1990-12-13 | — | — | WO | disclosed |
| CN-88102538-A | New dicyclic compound, its preparation method and the pharmaceutical composition that contains this compounds | — | 1988-12-07 | — | — | CN | disclosed |
| EP-0205180-A1 | Process for preparing virtually spherical catalyst particles and a process for polymerizing alkenes-1 and for copolymerizing alkenes-1 with each other and/or with ethylene while applying such spherical catalyst particles | STAMICARBON B.V. (NL) | 1986-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090184417-A1 | POLYOL PHOTOSENSITIZERS, CARRIER GAS UV LASER ABLATION SENSITIZERS, AND OTHER ADDITIVES AND METHODS FOR MAKING AND USING SAME | OTC, ODC1, OXGR1 | ESR1 1614/4885ESR2 2349/4885EGFR 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.